shire plc (SHPGF:OTC US)
Transactions by SHIRE PLC (SHPGF) in the last 6 months
ArmaGen Technologies, Inc. announced that it will receive funding from new investor Shire plc on July 23, 2014. The company will receive upfront payment of $15 million in cash and equity, an additional equity investment in the transaction.
AbbVie Inc. (NYSE:ABBV) made an indicative offer to acquire Shire plc (LSE:SHP) for £23.8 billion on May 5, 2014. Under the terms, AbbVie will pay £16.23 in cash and issue its 0.768 share for each share of Shire. AbbVie made a revised offer to acquire Shire for £24.4 billion on May 13, 2014. Under the terms, AbbVie will pay £17.13 in cash and issue its 0.768 share for each share of Shire. AbbVie made a revised offer to acquire Shire for £26.9 billion on May 30, 2014. ...
Shire plc (LSE:SHP) acquired Lumena Pharmaceuticals, Inc. from Pappas Ventures, RiverVest Venture Partners, LLC, Alta Partners LP, New Enterprise Associates, Adage Capital Management, L.P. and RA Capital Management, LLC for $260 million in cash and earnout payments on May 12, 2014. Shire will pay $260 million in cash, net cash payment at cloisng and near-term contingent milestone payments related to ongoing clinical trials. Shire does not expect the acquisition of Lumena ...
Alta Partners LP
New Enterprise Associates
RA Capital Management, LLC
RiverVest Venture Partners, LLC
Shire plc (LSE:SHP) entered into a definitive agreement to acquire Fibrotech Therapeutics Pty Ltd. from MRCF IIF, L.P, Brandon Biosciences Fund 1 IIF Partnership, L.P. and MRCF IIF, L.P., funds of Brandon Capital Partners, Universities Innovation Investment Trust, a fund of Uniseed Pty Limited, and others for $75 million on May 1, 2014. The consideration includes upfront payment of $75 million and certain contingent payments based on the achievement of development and ...
Brandon Capital Partners
MRCF IIF, L.P.
Uniseed Pty Limited
Universities Innovation Investment Trust
Shire plc (LSE:SHP) announces a share repurchase program. Under the program, the company will repurchase up to 58,896,580 ordinary shares, representing 10% of the issued share capital. The minimum price, which may be paid for an ordinary share is 5 pence. The maximum price, which may be paid for an ordinary share shall be the higher of an amount equal to 105% of the average of the middle market quotations for the company’s ordinary shares as taken from the London Stock ...
|Actavis plc||$214.26 USD||-1.29|
|Allergan Inc/United States||$165.86 USD||-6.31|
|Celgene Corp||$87.15 USD||-1.19|
|CSL Ltd||A$65.99 AUD||-1.81|
|Valeant Pharmaceuticals International Inc||C$127.83 CAD||-9.59|
|View Industry Companies|